Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA.

J Clin Oncol. 2010 Jan 10;28(2):357-60. doi: 10.1200/JCO.2009.24.7049. Epub 2009 Nov 30.

2.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology/College of American Pathologists.

Arch Pathol Lab Med. 2007;131(1):18-43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2.

PMID:
19548375
3.

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.

Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X, Comb MJ.

Clin Cancer Res. 2009 May 1;15(9):3023-8. doi: 10.1158/1078-0432.CCR-08-2739. Epub 2009 Apr 14.

4.

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M.

J Clin Oncol. 2009 Apr 1;27(10):1667-74. doi: 10.1200/JCO.2008.19.1635. Epub 2009 Mar 2.

5.

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A.

Br J Cancer. 2008 Sep 16;99(6):923-9. doi: 10.1038/sj.bjc.6604629.

6.

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S.

Cancer Res. 2008 Nov 15;68(22):9479-87. doi: 10.1158/0008-5472.CAN-08-1643.

7.

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Cappuzzo F, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M.

Ann Oncol. 2009 Feb;20(2):298-304. doi: 10.1093/annonc/mdn635. Epub 2008 Oct 3.

8.

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.

Toschi L, Jänne PA.

Clin Cancer Res. 2008 Oct 1;14(19):5941-6. doi: 10.1158/1078-0432.CCR-08-0071. Review.

9.

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.

Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR.

Cancer. 2008 Oct 15;113(8):2129-38. doi: 10.1002/cncr.23826.

10.

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA.

Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24.

11.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
12.

The role of gefitinib in the management of Asian patients with non-small cell lung cancer.

Chang AY.

Expert Opin Investig Drugs. 2008 Mar;17(3):401-11. doi: 10.1517/13543784.17.3.401 . Review. Erratum in: Expert Opin Investig Drugs. 2008 May;17(5):825.

PMID:
18321238
13.

Signaling networks assembled by oncogenic EGFR and c-Met.

Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD, Comb MJ.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692-7. doi: 10.1073/pnas.0707270105. Epub 2008 Jan 7.

14.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W.

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. Epub 2007 Dec 18.

15.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.

Science. 2007 May 18;316(5827):1039-43. Epub 2007 Apr 26.

16.

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.

Yoshida K, Yatabe Y, Park JY, Shimizu J, Horio Y, Matsuo K, Kosaka T, Mitsudomi T, Hida T.

J Thorac Oncol. 2007 Jan;2(1):22-8.

17.

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.

Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, Shimizu K, Tanaka S, Suga T, Hisada T, Ishizuka T, Saito R, Dobashi K, Mori M.

Lung Cancer. 2007 Jun;56(3):383-9. Epub 2007 Mar 26.

PMID:
17368623
18.

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS.

Cancer Res. 2007 Mar 1;67(5):2081-8. Erratum in: Cancer Res. 2007 Apr 15;67(8):3987.

19.

High-throughput oncogene mutation profiling in human cancer.

Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA.

Nat Genet. 2007 Mar;39(3):347-51. Epub 2007 Feb 11. Erratum in: Nat Genet. 2007 Apr;39(4):567. Macconnaill, Laura E [corrected to MacConaill, Laura].

PMID:
17293865
20.

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.

Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA.

J Clin Oncol. 2007 Mar 1;25(7):760-6. Epub 2007 Jan 16.

PMID:
17228019

Supplemental Content

Support Center